Featured Publications

INOVIO is focused on developing and commercializing DNA medicines to help protect people from infectious diseases and help treat people with cancer and HPV-associated diseases. In the last several years INOVIO has had its data published in several prominent peer-reviewed medical journals including:

INO-4800 DNA vaccine induces neutralizing antibodies and T cell activity against global SARS-CoV-2 variants

npj Vaccines
October 2021

SARS-CoV-2 DNA Vaccine INO-4800 Induces Durable Immune Responses Capable of Being Boosted in a Phase 1 Open-Label Trial

The Journal of Infectious Diseases
January 2022

571. Safety and Immunogenicity of INO-4800, a COVID-19 DNA Vaccine as a Primary Series and Booster

Open Forum Infectious Diseases
December 2021

Immunogenicity of a DNA vaccine candidate for COVID-19

Nature Communications
May 2020

Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial

The Lancet Infectious Diseases
July 2019

Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial

The Lancet
September 2015

Infectious Diseases (Non HPV-Associated)

Title	Disease Target	Product
Synthetic Consensus HIV-1 DNA Induces Potent Cellular Immune Responses and Synthesis of Granzyme B, Perforin in HIV Infected Individuals Molecular Therapy — March 2015	HIV	PENNVAX-GP
HIV-1 Env DNA Vaccine plus Protein Boost Delivered by EP Expands B- and T-Cell Responses and Neutralizing Phenotype In Vivo PLoS ONE — December 2013	HIV	PENNVAX-GP
Immunogenicity of a novel engineered HIV-1 clade C synthetic consensus-based envelope DNA vaccine Vaccine — September 2011	HIV	PENNVAX-GP
Intradermal SynCon® Ebola GP DNA Vaccine Is Temperature Stable and Safely Demonstrates Cellular and Humoral Immunogenicity Advantages in Healthy Volunteers The Journal of Infectious Diseases — March 2019	Ebola	INO-4201
Protective Efficacy and Long-Term Immunogenicity in Cynomolgus Macaques by Ebola Virus Glycoprotein Synthetic DNA Vaccines The Journal of Infectious Diseases — October 2018	Ebola	INO-4201
Rapid response to an emerging infectious disease – Lessons learned from development of a synthetic DNA vaccine targeting Zika virus Microbes and Infection — December 2018	Zika	INO-4600
Zika-Induced Male Infertility in Mice Is Potentially Reversible and Preventable by Deoxyribonucleic Acid Immunization The Journal of Infectious Diseases — July 2018	Zika	INO-4600
DNA vaccination protects mice against Zika virus-induced damage to the testes Nature Communications — June 2017	Zika	INO-4600
In vivo protection against ZIKV infection and pathogenesis through passive antibody transfer and active immunisation with a prMEnv DNA vaccine npj Vaccines — November 2016	Zika	INO-4600
A synthetic consensus anti–spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates Science Translational Medicine — August 2015	MERS	INO-4700
Broad cross-protective anti-hemagglutination responses elicited by influenza microconsensus DNA vaccine Vaccine — May 2018	Influenza
An engineered bispecific DNA-encoded IgG antibody protects against Pseudomonas aeruginosa in a pneumonia challenge model Nature Communications — September 2017	Pseudomonas
Rapid and Long-Term Immunity Elicited by DNA-Encoded Antibody Prophylaxis and DNA Vaccination Against Chikungunya Virus The Journal of Infectious Diseases — March 2016	Chikungunya
Protection against dengue disease by synthetic nucleic acid antibody prophylaxis/immunotherapy Scientific Reports — July 2015	Dengue
IFNL3-adjuvanted HCV DNA vaccine reduces regulatory T-cell frequency and increases virus-specific T-cell responses Journal of Hepatology — February 2020	Hepatitis C	GLS-6150
Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial The Lancet Infectious Diseases — July 2019	MERS	INO-4700
Safety and Immunogenicity of an Anti–Zika Virus DNA Vaccine — Preliminary Report The New England Journal of Medicine — October 2017	Zika	INO-4600

SUBSCRIBE FOR UPDATES FROM INOVIO
Register to receive email alerts for INOVIO press releases